The IDENTIFY Study: The Investigation and Detection of Urological Neoplasia in Patients Referred with Suspected Urinary Tract Cancer; A multicentre observational study

Sinan Khadhouri; Kevin M. Gallagher; Kenneth MacKenzie; Taimur T. Shah; Chuanyu Gao; Sacha Moore; Eleanor Zimmermann; Eric Edison; Matthew Jefferies; Arjun K. Nambiar; Miles  Mannas; Taeweon  Lee; Giancarlo  Marra; Beatrice  Lillaz; Juan Gómez Rivas; Jonathan  olivier; Mark  Assmus; Taha  Uçar; Francesco  Claps; Matteo  Boltri; Tara  Burnhope; Nkwam  Nkwam; George  Tanasescu; Nicholas  Boxall; Alison  Downey; Asim  Lal; Marta  Antón-Juanilla; Holly  Clarke; David  Lau; Kathryn  Gillams; Matthew  Crockett; Matthew E.  Nielsen; Yemisi Takwoingi; Naomi  Chuchu; John  O'Rourke; Graeme MacLennan; John McGrath; Veeru Kasivisvanathan; The IDENTIFY Study Group

doi:10.1111/bju.15483

The IDENTIFY Study: The Investigation and Detection of Urological Neoplasia in Patients Referred with Suspected Urinary Tract Cancer; A multicentre observational study

Sinan Khadhouri^* (Corresponding Author)
, Kevin M. Gallagher
, Kenneth MacKenzie
, Taimur T. Shah
, Chuanyu Gao
, Sacha Moore
, Eleanor Zimmermann
, Eric Edison
, Matthew Jefferies
, Arjun K. Nambiar
, Miles Mannas
, Taeweon Lee
, Giancarlo Marra
, Beatrice Lillaz
, Juan Gómez Rivas
, Jonathan olivier
, Mark Assmus
, Taha Uçar
, Francesco Claps
, Matteo Boltri

Tara Burnhope, Nkwam Nkwam, George Tanasescu, Nicholas Boxall, Alison Downey , Asim Lal, Marta Antón-Juanilla , Holly Clarke, David Lau, Kathryn Gillams , Matthew Crockett, Matthew E. Nielsen, Yemisi Takwoingi, Naomi Chuchu , John O'Rourke, Graeme MacLennan, John McGrath, Veeru Kasivisvanathan, The IDENTIFY Study Group

^*Corresponding author for this work

North Middlesex Hospital
British Urology Researchers in Surgical Training (BURST) Collaborative
City Hospitals Sunderland NHS Foundation Trust
Aneurin Bevan Health Board
Manchester Academic Health Science Centre
University of Birmingham
Universidad Autónoma de Madrid
European Association of Urology
Wrexham Maelor
Addenbrooke's Hospital
British Urology Researchers in Surgical Training (BURST)
University College London
West Hertfordshire Hospitals NHS Trust
NHS Lothian
National Health Service
Imperial College London
British Urology Researchers in Surgical Trainin Collaborative
University of British Columbia
Azienda Ospedaliera - Universitaria Città della Salute e della Scienza di Torino
SanGiovanni Battista Hospital, Turin
University of Exeter
Claude Huriez Hospital, Lille
University of Alberta
University of North Carolina Hospitals
Frimley Hospitals NHS Foundation Trust
Great Western Hospitals NHS Foundation Trust
Istanbul Medeniyet University
University of Trieste
University Hospitals of Derby and Burton NHS Foundation Trust
Queen Alexandra Hospital
Salford Royal NHS Foundation Trust
Doncaster Royal Infirmary
Hospital Universitario Cruces, Barakaldo
Bradford Teaching Hospitals NHS Foundation Trust
University of Aberdeen

Research output: Contribution to journal › Article › peer-review

58 Citations (Scopus)

14 Downloads (Pure)

Abstract

To evaluate the contemporary prevalence of urinary tract cancer (bladder cancer, upper tract urothelial cancer (UTUC) and renal cancer) in patients referred to secondary care with haematuria, adjusted for established patient risk markers and geographical variation. This was an international multicentre prospective observational study. We included patients aged 16 and over, referred to secondary care with suspected urinary tract cancer. Patients with a known or previous urological malignancy were excluded. We estimated the prevalence of bladder cancer, UTUC, renal cancer and prostate cancer; stratified by age, type of haematuria, sex and smoking. We used a multivariable mixed effects logistic regression to adjust cancer prevalence for age, type of haematuria, sex, smoking, hospitals and countries. Of the 11,059 patients assessed for eligibility, 10,896 were included from 110 hospitals across 26 countries. The overall adjusted cancer prevalence (n=2257) was 28.2% (95% CI 22.3-34.1), bladder cancer (n=1951) 24.7% (19.1-30.2), UTUC (n=128) 1.14% (0.77-1.52), renal cancer (n=107) 1.05% (0.80-1.29) and prostate cancer (n=124) 1.75% (1.32-2.18). Odds ratios for patient risk markers in the model for all cancers were: Age 1.04 (95% CI 1.03-1.05) p

Original language	English
Pages (from-to)	440-450
Number of pages	12
Journal	BJU International
Volume	128
Issue number	4
Early online date	8 Sept 2021
DOIs	https://doi.org/10.1111/bju.15483
Publication status	Published - 1 Oct 2021

Bibliographical note

Funding
Grants from Action Bladder Cancer UK, The Urology Foundation, The Rosetrees Trust were used for costs of statistical analysis and dissemination of results at international meetings and conferences. There were no endorsements from pharmaceutical companies or agencies to write this article. The corresponding author (Sinan Khadhouri) had full access to the data and held the final responsibility to submit the manuscript. Action Bladder Cancer UK, The Urology Foundation, The Rosetrees Trust.

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

haematuria
bladder cancer
upper tract urothelial cancer
renal cancer
cancer prevalence
urinary tract cancer
prostate cancer

Access to Document

10.1111/bju.15483Licence: CC BY-NC

Khadhouri_etal_BJUI_The_IDENTIFY_study_VOR
This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.https://creativecommons.org/licenses/by-nc/4.0/
Final published version, 1.12 MBLicence: CC BY-NC

Cite this

Khadhouri, S., Gallagher, K. M., MacKenzie, K., Shah, T. T., Gao, C., Moore, S., Zimmermann, E., Edison, E., Jefferies, M., Nambiar, A. K., Mannas, M., Lee , T., Marra , G., Lillaz , B., Gómez Rivas, J., olivier, J., Assmus , M., Uçar, T., Claps, F., ... The IDENTIFY Study Group (2021). The IDENTIFY Study: The Investigation and Detection of Urological Neoplasia in Patients Referred with Suspected Urinary Tract Cancer; A multicentre observational study. BJU International, 128(4), 440-450. https://doi.org/10.1111/bju.15483

The IDENTIFY Study: The Investigation and Detection of Urological Neoplasia in Patients Referred with Suspected Urinary Tract Cancer; A multicentre observational study. / Khadhouri, Sinan (Corresponding Author); Gallagher, Kevin M.; MacKenzie, Kenneth et al.
In: BJU International, Vol. 128, No. 4, 01.10.2021, p. 440-450.

Research output: Contribution to journal › Article › peer-review

Khadhouri, S, Gallagher, KM, MacKenzie, K, Shah, TT, Gao, C, Moore, S, Zimmermann, E, Edison, E, Jefferies, M, Nambiar, AK, Mannas, M, Lee , T, Marra , G, Lillaz , B, Gómez Rivas, J, olivier, J, Assmus , M, Uçar, T, Claps, F, Boltri , M, Burnhope, T, Nkwam, N, Tanasescu, G, Boxall, N, Downey , A, Lal, A, Antón-Juanilla , M, Clarke, H, Lau, D, Gillams , K, Crockett, M, Nielsen, ME, Takwoingi, Y, Chuchu , N, O'Rourke, J, MacLennan, G, McGrath, J, Kasivisvanathan, V & The IDENTIFY Study Group 2021, 'The IDENTIFY Study: The Investigation and Detection of Urological Neoplasia in Patients Referred with Suspected Urinary Tract Cancer; A multicentre observational study', BJU International, vol. 128, no. 4, pp. 440-450. https://doi.org/10.1111/bju.15483

@article{53020789aebf44c6a53ef2c5fdef9374,

title = "The IDENTIFY Study: The Investigation and Detection of Urological Neoplasia in Patients Referred with Suspected Urinary Tract Cancer; A multicentre observational study",

abstract = "To evaluate the contemporary prevalence of urinary tract cancer (bladder cancer, upper tract urothelial cancer (UTUC) and renal cancer) in patients referred to secondary care with haematuria, adjusted for established patient risk markers and geographical variation. This was an international multicentre prospective observational study. We included patients aged 16 and over, referred to secondary care with suspected urinary tract cancer. Patients with a known or previous urological malignancy were excluded. We estimated the prevalence of bladder cancer, UTUC, renal cancer and prostate cancer; stratified by age, type of haematuria, sex and smoking. We used a multivariable mixed effects logistic regression to adjust cancer prevalence for age, type of haematuria, sex, smoking, hospitals and countries. Of the 11,059 patients assessed for eligibility, 10,896 were included from 110 hospitals across 26 countries. The overall adjusted cancer prevalence (n=2257) was 28.2\% (95\% CI 22.3-34.1), bladder cancer (n=1951) 24.7\% (19.1-30.2), UTUC (n=128) 1.14\% (0.77-1.52), renal cancer (n=107) 1.05\% (0.80-1.29) and prostate cancer (n=124) 1.75\% (1.32-2.18). Odds ratios for patient risk markers in the model for all cancers were: Age 1.04 (95\% CI 1.03-1.05) p",

keywords = "haematuria, bladder cancer, upper tract urothelial cancer, renal cancer, cancer prevalence, urinary tract cancer, prostate cancer",

author = "Sinan Khadhouri and Gallagher, \{Kevin M.\} and Kenneth MacKenzie and Shah, \{Taimur T.\} and Chuanyu Gao and Sacha Moore and Eleanor Zimmermann and Eric Edison and Matthew Jefferies and Nambiar, \{Arjun K.\} and Miles Mannas and Taeweon Lee and Giancarlo Marra and Beatrice Lillaz and \{G{\'o}mez Rivas\}, Juan and Jonathan olivier and Mark Assmus and Taha U{\c c}ar and Francesco Claps and Matteo Boltri and Tara Burnhope and Nkwam Nkwam and George Tanasescu and Nicholas Boxall and Alison Downey and Asim Lal and Marta Ant{\'o}n-Juanilla and Holly Clarke and David Lau and Kathryn Gillams and Matthew Crockett and Nielsen, \{Matthew E.\} and Yemisi Takwoingi and Naomi Chuchu and John O'Rourke and Graeme MacLennan and John McGrath and Veeru Kasivisvanathan and \{The IDENTIFY Study Group\}",

note = "Funding Grants from Action Bladder Cancer UK, The Urology Foundation, The Rosetrees Trust were used for costs of statistical analysis and dissemination of results at international meetings and conferences. There were no endorsements from pharmaceutical companies or agencies to write this article. The corresponding author (Sinan Khadhouri) had full access to the data and held the final responsibility to submit the manuscript. Action Bladder Cancer UK, The Urology Foundation, The Rosetrees Trust.",

year = "2021",

month = oct,

day = "1",

doi = "10.1111/bju.15483",

language = "English",

volume = "128",

pages = "440--450",

journal = "BJU International",

issn = "1464-4096",

publisher = "John Wiley and Sons Inc.",

number = "4",

}

TY - JOUR

T1 - The IDENTIFY Study

T2 - The Investigation and Detection of Urological Neoplasia in Patients Referred with Suspected Urinary Tract Cancer; A multicentre observational study

AU - Khadhouri, Sinan

AU - Gallagher, Kevin M.

AU - MacKenzie, Kenneth

AU - Shah, Taimur T.

AU - Gao, Chuanyu

AU - Moore, Sacha

AU - Zimmermann, Eleanor

AU - Edison, Eric

AU - Jefferies, Matthew

AU - Nambiar, Arjun K.

AU - Mannas, Miles

AU - Lee , Taeweon

AU - Marra , Giancarlo

AU - Lillaz , Beatrice

AU - Gómez Rivas, Juan

AU - olivier, Jonathan

AU - Assmus , Mark

AU - Uçar, Taha

AU - Claps, Francesco

AU - Boltri , Matteo

AU - Burnhope, Tara

AU - Nkwam, Nkwam

AU - Tanasescu, George

AU - Boxall, Nicholas

AU - Downey , Alison

AU - Lal, Asim

AU - Antón-Juanilla , Marta

AU - Clarke, Holly

AU - Lau, David

AU - Gillams , Kathryn

AU - Crockett, Matthew

AU - Nielsen, Matthew E.

AU - Takwoingi, Yemisi

AU - Chuchu , Naomi

AU - O'Rourke, John

AU - MacLennan, Graeme

AU - McGrath, John

AU - Kasivisvanathan, Veeru

AU - The IDENTIFY Study Group

N1 - Funding Grants from Action Bladder Cancer UK, The Urology Foundation, The Rosetrees Trust were used for costs of statistical analysis and dissemination of results at international meetings and conferences. There were no endorsements from pharmaceutical companies or agencies to write this article. The corresponding author (Sinan Khadhouri) had full access to the data and held the final responsibility to submit the manuscript. Action Bladder Cancer UK, The Urology Foundation, The Rosetrees Trust.

PY - 2021/10/1

Y1 - 2021/10/1

N2 - To evaluate the contemporary prevalence of urinary tract cancer (bladder cancer, upper tract urothelial cancer (UTUC) and renal cancer) in patients referred to secondary care with haematuria, adjusted for established patient risk markers and geographical variation. This was an international multicentre prospective observational study. We included patients aged 16 and over, referred to secondary care with suspected urinary tract cancer. Patients with a known or previous urological malignancy were excluded. We estimated the prevalence of bladder cancer, UTUC, renal cancer and prostate cancer; stratified by age, type of haematuria, sex and smoking. We used a multivariable mixed effects logistic regression to adjust cancer prevalence for age, type of haematuria, sex, smoking, hospitals and countries. Of the 11,059 patients assessed for eligibility, 10,896 were included from 110 hospitals across 26 countries. The overall adjusted cancer prevalence (n=2257) was 28.2% (95% CI 22.3-34.1), bladder cancer (n=1951) 24.7% (19.1-30.2), UTUC (n=128) 1.14% (0.77-1.52), renal cancer (n=107) 1.05% (0.80-1.29) and prostate cancer (n=124) 1.75% (1.32-2.18). Odds ratios for patient risk markers in the model for all cancers were: Age 1.04 (95% CI 1.03-1.05) p

AB - To evaluate the contemporary prevalence of urinary tract cancer (bladder cancer, upper tract urothelial cancer (UTUC) and renal cancer) in patients referred to secondary care with haematuria, adjusted for established patient risk markers and geographical variation. This was an international multicentre prospective observational study. We included patients aged 16 and over, referred to secondary care with suspected urinary tract cancer. Patients with a known or previous urological malignancy were excluded. We estimated the prevalence of bladder cancer, UTUC, renal cancer and prostate cancer; stratified by age, type of haematuria, sex and smoking. We used a multivariable mixed effects logistic regression to adjust cancer prevalence for age, type of haematuria, sex, smoking, hospitals and countries. Of the 11,059 patients assessed for eligibility, 10,896 were included from 110 hospitals across 26 countries. The overall adjusted cancer prevalence (n=2257) was 28.2% (95% CI 22.3-34.1), bladder cancer (n=1951) 24.7% (19.1-30.2), UTUC (n=128) 1.14% (0.77-1.52), renal cancer (n=107) 1.05% (0.80-1.29) and prostate cancer (n=124) 1.75% (1.32-2.18). Odds ratios for patient risk markers in the model for all cancers were: Age 1.04 (95% CI 1.03-1.05) p

KW - haematuria

KW - bladder cancer

KW - upper tract urothelial cancer

KW - renal cancer

KW - cancer prevalence

KW - urinary tract cancer

KW - prostate cancer

U2 - 10.1111/bju.15483

DO - 10.1111/bju.15483

M3 - Article

SN - 1464-4096

VL - 128

SP - 440

EP - 450

JO - BJU International

JF - BJU International

IS - 4

ER -

The IDENTIFY Study: The Investigation and Detection of Urological Neoplasia in Patients Referred with Suspected Urinary Tract Cancer; A multicentre observational study

Abstract

Bibliographical note

UN SDGs

Keywords

Access to Document

Fingerprint

Cite this